Harish Dhingra
Adolescent Medicine · Bedford, TXNPI 1710931530
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 92 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 29 manufacturers, the largest accounting for just 16.9% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2019 at $1,251 and has fallen 78.2% since, to $273 in 2025.
Across 92 payments — averaging $32.15 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Teva Pharmaceuticals USA, Inc.$499
- Otsuka America Pharmaceutical, Inc.$374
- AbbVie$315
- Abbott$263
- Novo Nordisk$246
- E.r. Squibb & Sons, L.L.C.$135
- plus $1K from 23 others
What the payments were for
- Food & beverage$2,957100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Teva Pharmaceuticals USA, Inc. | 7 | $499 |
| Otsuka America Pharmaceutical, Inc. | 5 | $374 |
| AbbVie | 3 | $315 |
| Abbott | 12 | $263 |
| Novo Nordisk | 11 | $246 |
| E.r. Squibb & Sons, L.L.C. | 1 | $135 |
| Sunovion Pharmaceuticals Inc. | 3 | $128 |
| Neurocrine Biosciences, Inc. | 1 | $96 |
| Bayer | 5 | $91 |
| Astellas Pharma US Inc | 5 | $87 |
| Amgen | 5 | $85 |
| AstraZeneca | 5 | $81 |
| Shield Therapeutics Inc | 1 | $76 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 3 | $54 |
| Johnson & Johnson | 5 | $53 |
| Boehringer Ingelheim | 3 | $49 |
| Merck | 2 | $42 |
| Exact Sciences | 2 | $41 |
| Novartis | 2 | $40 |
| Lundbeck LLC | 2 | $33 |
| SK Life Science, Inc. | 1 | $25 |
| Acadia Pharmaceuticals Inc | 1 | $22 |
| Corcept Therapeutics | 1 | $22 |
| Dexcom, Inc. | 1 | $19 |
| Mannkind Corporation | 1 | $18 |
| Lilly USA, LLC | 1 | $18 |
| CMP Pharma, Inc. | 1 | $16 |
| Nestle Healthcare Nutrition Inc. | 1 | $16 |
| GSK | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- AUSTEDO$238
- VRAYLAR$231
- Austedo XR$227
- COBENFY$135
- ABILIFY ASIMTUFII$125
- ABILIFY MAINTENA$125
- REXULTI$118
- Ozempic$101
How this compares
$2,957 in reported general payments places this provider in the 85th percentile of 68 adolescent medicine providers in Texas.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 23 | $648 |
| Atorvastatin Calcium | 26 | $281 |
| Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav | 21 | $215 |
| Tramadol Hcl | 11 | $170 |
| Escitalopram Oxalate | 11 | $75 |
| Amlodipine Besylate | 21 | $56 |
| Montelukast Sodium | 13 | $56 |
| Rosuvastatin Calcium | 11 | $50 |
| Lisinopril | 17 | $45 |
Paid to pharmacies, not to this prescriber.
Other adolescent medicine in Bedford
- Joan PurcellThe Woodlands$87K
- Amy MiddlemanHouston$70K
- Augustine ElejeEl Paso$37K
- Richard RuppGalveston$20K
- Scott SpearEdinburg$11K
- Marcy BerryPlano$7K
- Marlo BrawnerLivingston$4K
- Dana Rubin-RemerDallas$4K
- Surainder AjmaniHouston$3K
- Sharonda TaylorHouston$2K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.